04:27 AM EST, 12/06/2024 (MT Newswires) -- Innate Pharma ( IPHA ) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.

The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.

To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.

The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.

Shares of Innate Pharma ( IPHA ) rose more than 12% in premarket activity.